Amgen Statistics
Total Valuation
Amgen has a market cap or net worth of $224.48 billion. The enterprise value is $267.79 billion.
| Market Cap | 224.48B |
| Enterprise Value | 267.79B |
Important Dates
The last earnings date was Tuesday, August 4, 2026, after market close.
| Earnings Date | Aug 4, 2026 |
| Ex-Dividend Date | Aug 21, 2026 |
Share Statistics
Amgen has 540.63 million shares outstanding. The number of shares has increased by 0.46% in one year.
| Current Share Class | 540.63M |
| Shares Outstanding | 540.63M |
| Shares Change (YoY) | +0.46% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.17% |
| Owned by Institutions (%) | 81.32% |
| Float | 539.15M |
Valuation Ratios
The trailing PE ratio is 25.80 and the forward PE ratio is 17.73. Amgen's PEG ratio is 3.41.
| PE Ratio | 25.80 |
| Forward PE | 17.73 |
| PS Ratio | 5.89 |
| Forward PS | 5.62 |
| PB Ratio | 19.20 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 22.06 |
| P/OCF Ratio | 17.99 |
| PEG Ratio | 3.41 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 15.51, with an EV/FCF ratio of 26.32.
| EV / Earnings | 30.63 |
| EV / Sales | 7.03 |
| EV / EBITDA | 15.51 |
| EV / EBIT | 21.04 |
| EV / FCF | 26.32 |
Financial Position
The company has a current ratio of 1.37, with a Debt / Equity ratio of 4.90.
| Current Ratio | 1.37 |
| Quick Ratio | 0.95 |
| Debt / Equity | 4.90 |
| Debt / EBITDA | 3.27 |
| Debt / FCF | 5.63 |
| Interest Coverage | 4.14 |
Financial Efficiency
Return on equity (ROE) is 91.47% and return on invested capital (ROIC) is 19.76%.
| Return on Equity (ROE) | 91.47% |
| Return on Assets (ROA) | 8.67% |
| Return on Invested Capital (ROIC) | 19.76% |
| Return on Capital Employed (ROCE) | 18.14% |
| Weighted Average Cost of Capital (WACC) | 6.12% |
| Revenue Per Employee | $1.21M |
| Profits Per Employee | $277,556 |
| Employee Count | 31,500 |
| Asset Turnover | 0.42 |
| Inventory Turnover | 1.67 |
Taxes
In the past 12 months, Amgen has paid $1.54 billion in taxes.
| Income Tax | 1.54B |
| Effective Tax Rate | 15.01% |
Stock Price Statistics
The stock price has increased by +43.51% in the last 52 weeks. The beta is 0.41, so Amgen's price volatility has been lower than the market average.
| Beta (5Y) | 0.41 |
| 52-Week Price Change | +43.51% |
| 50-Day Moving Average | 370.22 |
| 200-Day Moving Average | 349.39 |
| Relative Strength Index (RSI) | 70.02 |
| Average Volume (20 Days) | 2,629,603 |
Short Selling Information
The latest short interest is 13.28 million, so 2.46% of the outstanding shares have been sold short.
| Short Interest | 13.28M |
| Short Previous Month | 12.85M |
| Short % of Shares Out | 2.46% |
| Short % of Float | 2.46% |
| Short Ratio (days to cover) | 5.66 |
Income Statement
In the last 12 months, Amgen had revenue of $38.10 billion and earned $8.74 billion in profits. Earnings per share was $16.09.
| Revenue | 38.10B |
| Gross Profit | 27.39B |
| Operating Income | 12.73B |
| Pretax Income | 10.29B |
| Net Income | 8.74B |
| EBITDA | 17.27B |
| EBIT | 12.73B |
| Earnings Per Share (EPS) | $16.09 |
Balance Sheet
The company has $13.99 billion in cash and $57.30 billion in debt, with a net cash position of -$43.32 billion or -$80.12 per share.
| Cash & Cash Equivalents | 13.99B |
| Total Debt | 57.30B |
| Net Cash | -43.32B |
| Net Cash Per Share | -$80.12 |
| Equity (Book Value) | 11.69B |
| Book Value Per Share | 21.62 |
| Working Capital | 9.46B |
Cash Flow
In the last 12 months, operating cash flow was $12.48 billion and capital expenditures -$2.30 billion, giving a free cash flow of $10.18 billion.
| Operating Cash Flow | 12.48B |
| Capital Expenditures | -2.30B |
| Depreciation & Amortization | 4.54B |
| Net Borrowing | 1.32B |
| Free Cash Flow | 10.18B |
| FCF Per Share | $18.82 |
Margins
Gross margin is 71.89%, with operating and profit margins of 33.40% and 22.95%.
| Gross Margin | 71.89% |
| Operating Margin | 33.40% |
| Pretax Margin | 27.00% |
| Profit Margin | 22.95% |
| EBITDA Margin | 45.33% |
| EBIT Margin | 33.40% |
| FCF Margin | 26.71% |
Dividends & Yields
This stock pays an annual dividend of $10.08, which amounts to a dividend yield of 2.43%.
| Dividend Per Share | $10.08 |
| Dividend Yield | 2.43% |
| Dividend Growth (YoY) | 5.86% |
| Years of Dividend Growth | 15 |
| Payout Ratio | 62.63% |
| Buyback Yield | -0.46% |
| Shareholder Yield | 1.97% |
| Earnings Yield | 3.89% |
| FCF Yield | 4.53% |
Analyst Forecast
The average price target for Amgen is $383.66, which is -7.60% lower than the current price. The consensus rating is "Buy".
| Price Target | $383.66 |
| Price Target Difference | -7.60% |
| Analyst Consensus | Buy |
| Analyst Count | 34 |
| Revenue Growth Forecast (3Y) | 3.84% |
| EPS Growth Forecast (3Y) | 5.11% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on November 22, 1999. It was a forward split with a ratio of 2:1.
| Last Split Date | Nov 22, 1999 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Amgen has an Altman Z-Score of 1.89 and a Piotroski F-Score of 8. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.89 |
| Piotroski F-Score | 8 |